Literature DB >> 26670093

Actual costs of cancer drugs in 15 European countries.

Wim H van Harten1, Anke Wind2, Paolo de Paoli3, Mahasti Saghatchian4, Simon Oberst5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26670093     DOI： 10.1016/S1470-2045(15)00486-6

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  25 in total

1.  Health policy: Affordability of drugs used in oncology health care.

Authors:  Stefan Sleijfer; Jaap Verweij
Journal:  Nat Rev Clin Oncol       Date:  2016-05-10       Impact factor: 66.675

2.  How should clinicians interpret conflicting cost-effectiveness analyses for the treatment of lymphoma across nations and payer models?

Authors:  R Andrew Harkins; Christopher R Flowers
Journal:  Leuk Lymphoma       Date:  2020-11-04

3.  Availability, Affordability, Access, and Pricing of Anti-cancer Medicines in Low- and Middle-Income Countries: A Systematic Review of Literature.

Authors:  Phyllis Ocran Mattila; Rabbiya Ahmad; Syed Shahzad Hasan; Zaheer-Ud-Din Babar
Journal:  Front Public Health       Date:  2021-04-30

4.  Talkin' About a Resolution: Issues in the Push for Greater Transparency of Medicine Prices.

Authors:  Brendan Shaw; Jorge Mestre-Ferrandiz
Journal:  Pharmacoeconomics       Date:  2020-02       Impact factor: 4.981

5.  Cancer drug expenditure in British Columbia and Saskatchewan: a trend analysis.

Authors:  Reka Pataky; David A Tran; Andrea Coronado; Riaz Alvi; Darryl Boehm; Dean A Regier; Stuart Peacock
Journal:  CMAJ Open       Date:  2018-07-27

6.  Quality to rely on: meeting report of the 5th Meeting of External Quality Assessment, Naples 2016.

Authors:  Han van Krieken; Sandi Deans; Jacqueline A Hall; Nicola Normanno; Fortunato Ciardiello; Jean-Yves Douillard
Journal:  ESMO Open       Date:  2016-11-18

7.  Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology.

Authors:  W H van Harten; V P Retèl
Journal:  Ecancermedicalscience       Date:  2016-10-28

Review 8.  Comparing assessment frameworks for cancer drugs between Canada and Europe: What can we learn from the differences?

Authors:  Matthew C Cheung; Kelvin Kw Chan; Mona Sabharwal; Anthony Fields; Alexandra Chambers; William K Evans
Journal:  ESMO Open       Date:  2017-02-22

9.  Responsible pricing in value-based assessment of cancer drugs: real-world data are an inevitable addition to select meaningful new cancer treatments.

Authors:  Wim van Harten; Maarten J IJzerman
Journal:  Ecancermedicalscience       Date:  2017-09-11

10.  Can Price Transparency Contribute to More Affordable Patient Access to Medicines?

Authors:  Sabine Vogler; Kenneth R Paterson
Journal:  Pharmacoecon Open       Date:  2017-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.